GuruTrack
UTHR

UTHR

UNITED THERAPEUTICS CORP

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary
UNITED THERAPEUTICS CORP (UTHR) is held as common stock by 8 tracked hedge-fund managers, with a combined reported value of ~$1.53B; the largest are Renaissance Technologies, Izzy Englander, Ken Griffin. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 2 added, 4 trimmed. 6 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · HighThis quarter · Mixed
Common-stock holders82 also report options
Congress trades6
Price$481.47vs quarter-end-11.14%
Sectors0
This quarter's moves
New1
Added2
Trimmed / sold4
Top holderRenaissance Technologies

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Ray DalioHold
Value $60.32M0.2% of portfolio111,3262026 Q2

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—
Value $135.13M— of portfolio249,4002026 Q2
Ken GriffinPUT—
Value $105.06M— of portfolio193,9002026 Q2
Izzy EnglanderCALL—
Value $39.72M— of portfolio73,3002026 Q2
Izzy EnglanderPUT—
Value $1.46M— of portfolio2,7002026 Q2

Insider Trading

Officers · directors · Form 4
Open-market purchases and sales (P/S)22

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$42.5K
    80 @ $531.62Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$231.3K
    441 @ $524.51Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$1.11M
    2,105 @ $526.76Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$634.3K
    1,200 @ $528.59Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$106.5K
    200 @ $532.63Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$661.9K
    1,264 @ $523.65Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$349.0K
    659 @ $529.56Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$1.13M
    2,135 @ $527.58Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$106.7K
    201 @ $531.01Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$470.4K
    895 @ $525.60Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$125.4K
    240 @ $522.49Traded 2026-08-19Filed 2026-08-20

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$970.2K
    1,880 @ $516.04Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$225.2K
    439 @ $513.06Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$121.8K
    239 @ $509.48Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$228.7K
    441 @ $518.65Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$451.4K
    873 @ $517.09Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$844.6K
    1,630 @ $518.19Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$1.20M
    2,333 @ $514.99Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$649.9K
    1,264 @ $514.18Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$117.9K
    231 @ $510.47Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$87.0K
    170 @ $511.59Traded 2026-08-18Filed 2026-08-19

  • Martine A Rothblatt

    Chairperson & CEO

    Sell$106.7K
    213 @ $501.06Traded 2026-08-17Filed 2026-08-18

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.